Results 61 to 70 of about 5,950 (190)

Adverse Events of Saffron (Crocus sativus L.): Systematic Review of Current Evidence

open access: yesHealth Science Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background Crocus sativus L., commonly known as saffron, is a widely used spice with a rich history of culinary and medicinal applications. This systematic review aims to compile human data from studies on monopreparations of C. sativus, including stigma powder and other extracts, to evaluate their safety.
Fatemeh Sadat Hasheminasab   +3 more
wiley   +1 more source

What is the addiction risk associated with tramadol? [PDF]

open access: yes, 2005
Tramadol (Ultram, generic and with acetaminophen in Ultracet) carries a risk of substance abuse (strength of recommendation [SOR]: B, based on case report surveillance programs).
Mackler, Leslie, McDiarmid, Todd
core  

Unlicensed and off-label prescription of respiratory drugs to children [PDF]

open access: yes, 2004
Many respiratory drugs are not available in formulations suitable for infants and toddlers. Efficacy and safety research is mostly restricted to older children.
Anker, J.N. (John) van den   +4 more
core   +3 more sources

Molecular Mechanisms of Resistance and Treatment Efficacy of Delamanid Against Mycobacterium tuberculosis: A Systematic Review

open access: yesHealth Science Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background and Aims Tuberculosis (TB) remains a major global health problem, and treatment progress is increasingly threatened by rising multidrug‐resistant tuberculosis (MDR‐TB). Delamanid (DLM), a nitroimidazole drug, has shown good efficacy and safety against both drug‐susceptible and drug‐resistant Mycobacterium tuberculosis (Mtb) strains.
Md. Mahmudul Islam   +19 more
wiley   +1 more source

In vitro and in vivo postmarketing surveillance of valsartan, alone or in combination with amlodipine or hydrochlorthiazide, among Palestinian hypertensive patients

open access: yesTherapeutics and Clinical Risk Management, 2016
Abdel Naser Zaid,1 Masshour Ghanem,2 Dua’a Shweiki,1 Hala Shtewi,1 Raja’ Shaheen,1 Sondos Al Helaly,1 Zeina Khayyat,1 Rowa’a Al Ramahi,1 Sa’ed H Zyoud1 1Department of Pharmacy, Faculty of Medicine & Health Sciences, An-Najah ...
Zaid AN   +8 more
doaj  

Reações adversas a medicamentos em pediatria: uma revisão sistemática de estudos prospectivos Adverse drug reactions in pediatrics: a systematic review of prospective studies

open access: yesRevista Brasileira de Saúde Materno Infantil, 2004
O objetivo desta revisão foi explorar e comparar as informações derivadas de estudos prospectivos sobre a incidência de reações adversas a medicamentos (RAM) em pediatria, publicados de janeiro de 1966 a novembro de 2003 em revistas indexadas nas bases ...
Djanilson Barbosa dos Santos   +1 more
doaj   +1 more source

Incentivizing the Utilization of Pharmacogenomics in Drug Development [PDF]

open access: yes, 2012
Pharmacogenomics, the study and development of compounds according to how an individual’s genes affects the body’s response to drugs, holds enormous promise for increasing the safety and efficiency of drug development while decreasing adverse reactions ...
Koch, Valerie Gutmann
core   +1 more source

Long‐Term Safety and Efficacy of Pegvaliase in Japanese Adults With Phenylketonuria: Final Results of a Phase III Trial

open access: yesJIMD Reports, Volume 67, Issue 3, May 2026.
ABSTRACT Phenylketonuria (PKU) is an inborn error of metabolism leading to phenylalanine (Phe) accumulation and consequent neurological, neurocognitive, and psychiatric symptoms. Pegvaliase, a pegylated recombinant phenylalanine ammonia lyase that metabolizes Phe, effectively reduced blood Phe in phase III studies in the United States. This multicenter,
Yoko Nakajima   +6 more
wiley   +1 more source

DRUG THERAPY AND PREGNANCY: UNKNOWN RISKS LEAD TO HARD CHOICES [REDACTED VERSION] [PDF]

open access: yes, 2012
This paper is a proposal to improve the quality of information available to pregnant patients in selecting treatment options. By providing drug companies with extended grants of exclusivity, the FDA has the ability to empower pregnant women to take ...
Goldstein, Lori M.
core  

Japanese Clinical Practice Guidelines for Vascular Tumors, Vascular Malformations, Lymphatic Malformations, and Lymphangiomatosis 2022

open access: yesThe Journal of Dermatology, Volume 53, Issue 5, Page e257-e356, May 2026.
ABSTRACT The objective was to prepare guidelines to perform the current optimum treatment by organizing effective and efficient treatments of hemangiomas and vascular malformations, confirming the safety, and systematizing treatment, employing evidence‐based medicine techniques and aimed at improvement of the outcomes.
Yoshiaki Kinoshita   +116 more
wiley   +1 more source

Home - About - Disclaimer - Privacy